Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis manag...
Saved in:
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-02-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X251317811 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|